Literature DB >> 20062996

Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis.

Soo-Kyung Cho1, Il Hwan Oh, Chan Kum Park, Sang-Cheol Bae, Yoon-Kyoung Sung.   

Abstract

TNF inhibitors are being used in a rapidly expanding number of rheumatoid arthritis (RA) patients due to their effectiveness and acceptable safety profiles. To date, concerns regarding the adverse effects of TNF inhibitors have focused on infections, hematologic malignancies, and demyelinating disorders. Recently, the development of autoantibodies and other autoimmunity has been increasingly reported. Here, we describe a 36-year-old RA patient in whom organizing pneumonia and systemic lupus erythematosus were detected during etanercept treatment.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20062996     DOI： 10.1007/s00296-009-1350-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  10 in total

Review 1.  Cryptogenic organising pneumonia.

Authors:  J-F Cordier
Journal:  Eur Respir J       Date:  2006-08       Impact factor: 16.671

Review 2.  The organizing pneumonias: an update and review.

Authors:  Cory Schlesinger; Michael N Koss
Journal:  Curr Opin Pulm Med       Date:  2005-09       Impact factor: 3.155

3.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors:  L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

4.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

5.  Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.

Authors:  Paola Caramaschi; Domenico Biasi; Marco Colombatti; Sara Pieropan; Nicola Martinelli; Antonio Carletto; Alessandro Volpe; Luisa Maria Pacor; Lisa Maria Bambara
Journal:  Rheumatol Int       Date:  2004-12-31       Impact factor: 2.631

6.  Radiographic appearance of bronchiolitis obliterans organizing pneumonia (BOOP) developing during Bucillamine treatment for rheumatoid arthritis.

Authors:  Takashi Kajiya; Atsushi Kuroda; Daisuke Hokonohara; Chuwa Tei
Journal:  Am J Med Sci       Date:  2006-07       Impact factor: 2.378

Review 7.  A simultaneous onset of organizing pneumonia and rheumatoid arthritis, along with a review of the literature.

Authors:  Shunsuke Mori; Isamu Cho; Yukinori Koga; Mineharu Sugimoto
Journal:  Mod Rheumatol       Date:  2007-12-26       Impact factor: 3.023

8.  Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.

Authors:  Larry W Moreland; Michael E Weinblatt; Edward C Keystone; Joel M Kremer; Richard W Martin; Michael H Schiff; James B Whitmore; Barbara W White
Journal:  J Rheumatol       Date:  2006-03-15       Impact factor: 4.666

9.  Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2004-06

Review 10.  Autoimmune diseases induced by TNF-targeted therapies.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Maria-Jose Soto; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-10       Impact factor: 4.098
  10 in total
  5 in total

Review 1.  Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases.

Authors:  Carmen Maria Lara Rojas; Elisabetta Borella; Lavinia Palma; Silvio Ragozzino; Enrique De Ramón; Ricardo Gomez-Huelgas; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 2.  Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.

Authors:  Robert W Hallowell; Maureen R Horton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 3.  The safety of biologic therapies in RA-associated interstitial lung disease.

Authors:  Meghna Jani; Nik Hirani; Eric L Matteson; William G Dixon
Journal:  Nat Rev Rheumatol       Date:  2013-12-24       Impact factor: 20.543

Review 4.  Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.

Authors:  Shunsuke Mori
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-08

Review 5.  Organizing Pneumonia in Rheumatoid Arthritis Patients: A Case-Based Review.

Authors:  Shunsuke Mori; Yukinori Koga; Mineharu Sugimoto
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.